50
Participants
Start Date
May 11, 2017
Primary Completion Date
April 25, 2018
Study Completion Date
June 14, 2018
ENT-01
Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
Placebo
Daily dosing with a placebo
Movement Disorders Division, Mt. Sinai School of Medicine, New York
Penn State Health, Department of Neurology, Hershey
Thomas Jefferson University, Department of Neurology, Philadelphia
Georgetown Universtiy, Department of Neurology, Washington D.C.
Neuroscience Research, University of Florida Jacksonville, Jacksonville
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
USF Health Byrd Parkinson's Disease Movement Disorders Center of Excellence, Tampa
Suncoast Neuroscience Associates, Inc, St. Petersburg
MEDSOL Clinical Research, Port Charlotte
Sarasota Memory Hospital Clinical Research Ctr., Sarasota
Parkinson's & Movement Disorders Center, UH Cleveland Medical Center, Cleveland
Riverhills Healthcare, Inc., Cincinnati
Quest Research Institute, Farmington Hills
Rocky Mountain Movement Disorders Center, PC, Englewood
Keck Hospital of University of Southern California, Los Angeles
Lead Sponsor
Enterin Inc.
INDUSTRY